0
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Isolation and characterization of a VHH targeting the Acinetobacter baumannii cell surface protein CsuA/B

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Abstract

          Acinetobacter baumannii is a Gram-negative bacterial pathogen that exhibits high intrinsic resistance to antimicrobials, with treatment often requiring the use of last-resort antibiotics. Antibiotic-resistant strains have become increasingly prevalent, underscoring a need for new therapeutic interventions. The aim of this study was to use A. baumannii outer membrane vesicles as immunogens to generate single-domain antibodies (VHHs) against bacterial cell surface targets. Llama immunization with the outer membrane vesicle preparations from four A. baumannii strains (ATCC 19606, ATCC 17961, ATCC 17975, and LAC-4) elicited a strong heavy-chain IgG response, and VHHs were selected against cell surface and/or extracellular targets. For one VHH, OMV81, the target antigen was identified using a combination of gel electrophoresis, mass spectrometry, and binding studies. Using these techniques, OMV81 was shown to specifically recognize CsuA/B, a protein subunit of the Csu pilus, with an equilibrium dissociation constant of 17 nM. OMV81 specifically bound to intact A. baumannii cells, highlighting its potential use as a targeting agent. We anticipate the ability to generate antigen-specific antibodies against cell surface A. baumannii targets could provide tools for further study and treatment of this pathogen.

          Key points

          •Llama immunization with bacterial OMV preparations for VHH generation

          •A. baumannii CsuA/B, a pilus subunit, identified by mass spectrometry as VHH target

          •High-affinity and specific VHH binding to CsuA/B and A. baumannii cells

          Supplementary Information

          The online version contains supplementary material available at 10.1007/s00253-023-12594-1.

          Related collections

          Most cited references39

          • Record: found
          • Abstract: found
          • Article: not found

          Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis

          The spread of antibiotic-resistant bacteria poses a substantial threat to morbidity and mortality worldwide. Due to its large public health and societal implications, multidrug-resistant tuberculosis has been long regarded by WHO as a global priority for investment in new drugs. In 2016, WHO was requested by member states to create a priority list of other antibiotic-resistant bacteria to support research and development of effective drugs.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: found
            Is Open Access

            Antibiotics and Bacterial Resistance in the 21st Century

            Dangerous, antibiotic resistant bacteria have been observed with increasing frequency over the past several decades. In this review the factors that have been linked to this phenomenon are addressed. Profiles of bacterial species that are deemed to be particularly concerning at the present time are illustrated. Factors including economic impact, intrinsic and acquired drug resistance, morbidity and mortality rates, and means of infection are taken into account. Synchronously with the waxing of bacterial resistance there has been waning antibiotic development. The approaches that scientists are employing in the pursuit of new antibacterial agents are briefly described. The standings of established antibiotic classes as well as potentially emerging classes are assessed with an emphasis on molecules that have been clinically approved or are in advanced stages of development. Historical perspectives, mechanisms of action and resistance, spectrum of activity, and preeminent members of each class are discussed.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: found
              Is Open Access

              The effects of antibiotics on the microbiome throughout development and alternative approaches for therapeutic modulation

              The widespread use of antibiotics in the past 80 years has saved millions of human lives, facilitated technological progress and killed incalculable numbers of microbes, both pathogenic and commensal. Human-associated microbes perform an array of important functions, and we are now just beginning to understand the ways in which antibiotics have reshaped their ecology and the functional consequences of these changes. Mounting evidence shows that antibiotics influence the function of the immune system, our ability to resist infection, and our capacity for processing food. Therefore, it is now more important than ever to revisit how we use antibiotics. This review summarizes current research on the short-term and long-term consequences of antibiotic use on the human microbiome, from early life to adulthood, and its effect on diseases such as malnutrition, obesity, diabetes, and Clostridium difficile infection. Motivated by the consequences of inappropriate antibiotic use, we explore recent progress in the development of antivirulence approaches for resisting infection while minimizing resistance to therapy. We close the article by discussing probiotics and fecal microbiota transplants, which promise to restore the microbiota after damage of the microbiome. Together, the results of studies in this field emphasize the importance of developing a mechanistic understanding of gut ecology to enable the development of new therapeutic strategies and to rationally limit the use of antibiotic compounds.
                Bookmark

                Author and article information

                Contributors
                Greg.Hussack@nrc-cnrc.gc.ca
                Journal
                Appl Microbiol Biotechnol
                Appl Microbiol Biotechnol
                Applied Microbiology and Biotechnology
                Springer Berlin Heidelberg (Berlin/Heidelberg )
                0175-7598
                1432-0614
                7 June 2023
                7 June 2023
                : 1-14
                Affiliations
                [1 ]GRID grid.24433.32, ISNI 0000 0004 0449 7958, Human Health Therapeutics Research Centre, National Research Council Canada, ; Ottawa, Ontario Canada
                [2 ]GRID grid.28046.38, ISNI 0000 0001 2182 2255, Department of Biochemistry, Microbiology and Immunology, , University of Ottawa, ; Ottawa, Ontario Canada
                [3 ]GRID grid.411793.9, ISNI 0000 0004 1936 9318, Department of Biology, Brock University, ; St. Catharines, Ontario Canada
                Author information
                https://orcid.org/0000-0003-0958-7728
                http://orcid.org/0000-0002-9852-6865
                Article
                12594
                10.1007/s00253-023-12594-1
                10246537
                37284893
                9c530ef2-1a08-44ad-935f-fe8fc6af7e08
                © Crown 2023

                Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

                History
                : 5 January 2023
                : 18 April 2023
                : 15 May 2023
                Funding
                Funded by: National Research Council Canada
                Categories
                Biotechnologically Relevant Enzymes and Proteins

                Biotechnology
                acinetobacter baumannii,antimicrobial resistance,csua/b,nanobody,outer membrane vesicle,pilus,single-domain antibody,vhh

                Comments

                Comment on this article